Dr. Reddy's Laboratories Q2 Earnings Call Highlights

Dr. Reddy's Laboratories (NYSE: RDY) expects to relaunch semaglutide in November 2026, with most supply going to Canada. Q2 North America generics revenue was $264M, down 29% YoY. The company received FDA approval for its rituximab biosimilar and launched nivolumab in India. Net cash as of Sept. 30 was INR 2,502 crore, with full-year capex expected at INR 1,600-1,700 crore.

Original reporting
Published Oct 23, 2026, 6:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 6:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Dr. Reddy's Laboratories Q2 Earnings Call Highlights — source image
Decision brief

The 30-second read

$RDYBullishMed
01

Why it matters

The earnings beat and pipeline progress are likely to drive short‑term buying interest, while guidance uncertainties keep longer‑term risk moderate.

02

Market read

Positive earnings and pipeline updates could lift RDY and influence peers in the generics and biosimilars space.

03

What to watch

Currency volatility and competitive pricing pressure in generic markets may limit margin expansion.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

Dr. Reddy's Q2 earnings call provided detailed segment performance, product launches, and guidance for upcoming periods.

Company-level read

Ticker impact

$RDYBullishHigh confidence
Context

Q2 earnings call disclosed new revenue figures, product launch updates and guidance for semaglutide relaunch and CDMO expansion.

Expected impact

likely upward pressure as market prices in improved guidance and FDA approval updates

Evidence & confidence

Revenue beat, new FDA approval for rituximab biosimilar and semaglutide relaunch plans provide fresh positive catalysts.

Market effects

Strengthens outlook for Indian generics and biosimilars sector.

May boost Indian pharma stocks and related CDMO peers.

Highlights continued demand for semaglutide and biosimilar oncology drugs worldwide.

Counterpoint

Potential execution risk on semaglutide scale‑up and regulatory delays could temper upside.

Key entities

  • Dr. Reddy's Laboratories

    Indian pharmaceutical manufacturer (NYSE:RDY).

  • Fresenius Kabi

    U.S. partner for rituximab biosimilar commercialization.

Related articles

$RDYHigh

Dr.Reddy's Wins Brazil Approval For Generic Ozempic Alternative

Dr. Reddy's Laboratories (RDY) received approval from Brazil's ANVISA for its generic semaglutide injection, a diabetes treatment similar to Novo Nordisk's Ozempic. The product will be marketed in Brazil, a key market with 16.6 million diabetes patients and a $244.6 million semaglutide market. RDY plans to launch the product via a partnership with Ache. RDY stock closed at $14.77, up 3.29%, and is down 0.10% in pre-market trading.

$RDYMed

Dr Reddy's Laboratories Ltd (RDY) (Q2 2027) Earnings Call Highlights: Margin Recovery

Dr. Reddy's Laboratories reported a 1.5% year-over-year revenue decline, driven by lower lenalidomide sales and declines in North America, Europe, and PSAI businesses. The company expects margins to improve with new products and business mix, targeting a 55% gross margin. Semaglutide relaunch is planned for November 2026, and abatacept biosimilar approval is expected by December 2026.

$RDYHigh

DR REDDYS LABORATORIES LTD (RDY): Financial results for H1 2027

DR REDDYS LABORATORIES LTD (RDY) furnished an SEC Form 6-K — earnings release. Exhibit 99.2 CONTACT DR. REDDY’S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. Investor relationS Media relationS AISHWARYA SITHARAM SANTOSH VYAS aishwaryasitharam@drreddys.com santoshvyas@drreddys.com Dr. Reddy’s Q2 & H1FY27 Financia